Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by bfwon Jun 20, 2018 9:12am

217 Views

Post# 28197447

RE:Will Shorting Rise Again After The Last Decline ? ? ?

Smells like fear.

Shorts (especially naked ones) would only be so happy to see longs fold here at the spectre of a renewed short attack.

I’m far more interested in the closing bell rather than the opening bell.

Amateurs open the market...the pros close it.

bfw

G1945V wrote:
FDA's pathway for Apabetalone was the impetus for short selling to continue by hyping the SP all the way up to $2.70+ just to short it once again to repeat that cycle all the way to the primary endpoint of Apabetalone, BETonMACE clinical trial.

Is this what 's happening?......Can management do anything to stop it?

Let's see what the opening bell says today.

jmo
G1945V